Vivos Therapeutics chairman and CEO Kirk Huntsman joins Natalie Stoberman from the Proactive studio to discuss how the company's POD device performed a highly effective rate in treating migraine headaches in a clinical study.

Huntsman says the study showed 92% of patients reporting complete resolution of their symptoms, which is an unprecedented result for a non-pharmaceutical application in this field. He adds that the device has potential for other applications, such as treating upper airway resistance, TMD, bruxism, and various pain conditions, but further research and FDA indications are required.

Vivos Therapeutics has also reported an accelerated timeline for reaching positive cash flow. Huntsman says Vivos has implemented a broad set of initiatives aimed at improving operational efficiencies, reducing expenses, and positioning Vivos to take advantage of current growth opportunities. Now, the company projects it could hit the positive milestone at the beginning of 2024.

Proactive Investors

+1 347-449-0879

na-editorial@proactiveinvestors.com